Finally, in HER2 (human EGF receptor 2)-positive breast cancers, the overexpression of miR-21 leads to resistance to chemotherapy and immunotherapy targeting HER2 in an EMT-inducing manner [107]. This evidence concerns the gene ERBB2 and breast cancer.